Last reviewed 2026-05-19 · How we verify

elderly aged over 60

Adimmune Corporation · Phase 1 active Biologic ✓ Verified May 2026 Quality 15/100

elderly aged over 60 is a Biologic drug developed by Adimmune Corporation. It is currently in Phase 1 development.

Elderly individuals aged over 60 may benefit from interventions such as cognitive training and transcranial direct current stimulation (tDCS) to address conditions related to aging, eating behavior, and body image. Research on small molecule interventions for elderly individuals is not mentioned in the provided facts, but studies have investigated the effects of tDCS on cognitive function in this age group.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	elderly aged over 60
Sponsor	Adimmune Corporation
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

Pain
Headache
Fatigue
Myalgia
Swelling
Arthralgia
Redness
Skin cancer spot removal
Injection site pain
Sweating
Chills
Erythema

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

elderly aged over 60 CI brief — competitive landscape report
elderly aged over 60 updates RSS · CI watch RSS
Adimmune Corporation portfolio CI

Frequently asked questions about elderly aged over 60

What is elderly aged over 60?

elderly aged over 60 is a Biologic drug developed by Adimmune Corporation.

Who makes elderly aged over 60?

elderly aged over 60 is developed by Adimmune Corporation (see full Adimmune Corporation pipeline at /company/adimmune-corporation).

What development phase is elderly aged over 60 in?

elderly aged over 60 is in Phase 1.

What are the side effects of elderly aged over 60?

Common side effects of elderly aged over 60 include Pain, Headache, Fatigue, Myalgia, Swelling, Arthralgia.

Manufacturer: Adimmune Corporation — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing